Pulmonology Medical News about NSCLC;clinicopathological features;epigenetic inactivation;Homeobox A5 gene

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. EGFR inhibitors as first-line therapy in advanced non-small cell lung cancer

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Epigenetic inactivation of Homeobox A5 gene in nonsmall cell lung cancer and its relationship with clinicopathological features
Molecular Carcinogenesis, 06/30/09

Kim DS et al. - In a trial to explore the role of Homeobox A5 (HOXA5) in non-small cell lung cancer (NSCLC), it was shown that downregulation of the HOXA5 gene by aberrant promoter methylation occurs in the vast majority of NSCLCs and it may play a role in the pathogenesis of NSCLC.

Methods

Methylation status of the promoter region of the HOXA5 gene was investigated in NSCLCs using nested and standard methylation-specific PCR (MSP).
Methylation status with clinicopathological features was correlated.

Results

With standard MSP analysis, HOXA5 methylation was found in 113 (81.3%) of 139 NSCLCs and 72 (51.8%) in their corresponding nonmalignant lung tissues.
RT-PCR and immunohistochemical analysis showed that HOXA5 methylation correlates with gene expression.
In pts with stage I disease, HOXA5 methylation was more frequent in smokers than in never-smokes.
There was no influence of HOXA5 methylation on survival in all NSCLCs or at stages II-IV.
In patients with stage I disease, HOXA5 methylation was associated with a borderline significantly worse survival.

<< Previous
Predictors of successful weaning from prolonged mechanical...

Next >>
Severe Hypoxemia Due to Intrapulmonary Shunting Requiring Surgery...